Beyond Abstinence: Measuring Outcomes for SUD

BEYOND ABSTINENCE: Measuring Outcomes for SUD

Measuring treatment success for Substance Use Disorders (SUD) cannot be limited to an abstinence-only focus. However, to date, there is little consensus for measuring outcomes and success in the context of recovery.

Question Title

* 1. What is your full name?

Question Title

* 2. What is your work email address?

Question Title

* 3. What is the name of your organization?

Question Title

* 4. What is your professional title?

Question Title

* 5. Please rank the importance of the following clinical domains, with relation to their impact on SUD treatment outcomes. (Order these top to bottom, with top being the most important and bottom being the least important)

Question Title

* 6. Is there something else we should we consider in analyzing SUD outcomes?

Question Title

* 7. Rate your organization's ability to access information in each of these clinical domains.

	Not accessible	Somewhat accessible	Easily accessible
Risk Reduction (e.g., overall mortality, ER visits/all-cause hospitalizations, using in safer manner)	Risk Reduction (e.g., overall mortality, ER visits/all-cause hospitalizations, using in safer manner) Not accessible	Risk Reduction (e.g., overall mortality, ER visits/all-cause hospitalizations, using in safer manner) Somewhat accessible	Risk Reduction (e.g., overall mortality, ER visits/all-cause hospitalizations, using in safer manner) Easily accessible
Changes in Drug Use Patterns (e.g., fewer occasions of use per day and/or reduced use per occasion)	Changes in Drug Use Patterns (e.g., fewer occasions of use per day and/or reduced use per occasion) Not accessible	Changes in Drug Use Patterns (e.g., fewer occasions of use per day and/or reduced use per occasion) Somewhat accessible	Changes in Drug Use Patterns (e.g., fewer occasions of use per day and/or reduced use per occasion) Easily accessible
Patient/Family Reported Measures (Quality of Life)	Patient/Family Reported Measures (Quality of Life) Not accessible	Patient/Family Reported Measures (Quality of Life) Somewhat accessible	Patient/Family Reported Measures (Quality of Life) Easily accessible
Work/School Productivity (Presenteeism, Absenteeism)	Work/School Productivity (Presenteeism, Absenteeism) Not accessible	Work/School Productivity (Presenteeism, Absenteeism) Somewhat accessible	Work/School Productivity (Presenteeism, Absenteeism) Easily accessible
Impact of Clinical Co-morbidities (Management of comorbid anxiety, depression, diabetes, HIV, etc)	Impact of Clinical Co-morbidities (Management of comorbid anxiety, depression, diabetes, HIV, etc) Not accessible	Impact of Clinical Co-morbidities (Management of comorbid anxiety, depression, diabetes, HIV, etc) Somewhat accessible	Impact of Clinical Co-morbidities (Management of comorbid anxiety, depression, diabetes, HIV, etc) Easily accessible
Treatment Adherence (medication compliance, psychotherapy/peer support visits in the past month)	Treatment Adherence (medication compliance, psychotherapy/peer support visits in the past month) Not accessible	Treatment Adherence (medication compliance, psychotherapy/peer support visits in the past month) Somewhat accessible	Treatment Adherence (medication compliance, psychotherapy/peer support visits in the past month) Easily accessible
Achieving Patient Goals	Achieving Patient Goals Not accessible	Achieving Patient Goals Somewhat accessible	Achieving Patient Goals Easily accessible

Question Title

* 8. What is the process your organization has in place today to collect, measure, and analyze non-abstinence related SUD outcomes?

Question Title

* 9. What do you consider to be your biggest pain point related to measuring non-abstinence related SUD outcomes?